Compare NGNE & SCHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | SCHL |
|---|---|---|
| Founded | 2003 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Books |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 790.4M |
| IPO Year | 2014 | 1995 |
| Metric | NGNE | SCHL |
|---|---|---|
| Price | $35.99 | $41.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $63.57 | $40.00 |
| AVG Volume (30 Days) | 174.1K | ★ 374.7K |
| Earning Date | 05-08-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | 0.93 | ★ 3442.86 |
| EPS | N/A | ★ 2.34 |
| Revenue | N/A | ★ $1,487,100,000.00 |
| Revenue This Year | N/A | $1.88 |
| Revenue Next Year | N/A | $4.05 |
| P/E Ratio | ★ N/A | $17.77 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $22.69 |
| 52 Week High | $43.66 | $48.07 |
| Indicator | NGNE | SCHL |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 44.65 |
| Support Level | $31.83 | $40.29 |
| Resistance Level | $43.66 | $43.84 |
| Average True Range (ATR) | 2.07 | 1.77 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 72.75 | 44.58 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.